These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15728401)

  • 1. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation.
    Kanno Y; Okada H; Yamaji Y; Nakazato Y; Suzuki H
    QJM; 2005 Mar; 98(3):199-203. PubMed ID: 15728401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
    Kanno Y; Okada H; Saruta T; Suzuki H
    Clin Nephrol; 2000 Nov; 54(5):360-5. PubMed ID: 11105796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
    J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
    Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
    Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial.
    Boero R; Rollino C; Massara C; Vagelli G; Gonella M; Berto IM; Bajardi P; Perosa P; Malcangi U; Giorgi MP; Ghezzi PM; Borzumati M; Baroni AM; Cogno C; Triolo G; Angelini D; Antonelli A; Quarello F
    J Nephrol; 2001; 14(1):15-8. PubMed ID: 11281338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
    Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
    Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid Project database.
    Ardissino G; Viganò S; Testa S; Daccò V; Paglialonga F; Leoni A; Belingheri M; Avolio L; Ciofani A; Claris-Appiani A; Cusi D; Edefonti A; Ammenti A; Cecconi M; Fede C; Ghio L; La Manna A; Maringhini S; Papalia T; Pela I; Pisanello L; Ratsch IM;
    Nephrol Dial Transplant; 2007 Sep; 22(9):2525-30. PubMed ID: 17526542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of IgA nephropathy with angiotensin converting enzyme inhibitors: design of a prospective randomized multicenter trial.
    Coppo R; Chiesa M; Peruzzi L; Amore A
    J Nephrol; 2001; 14(6):447-52. PubMed ID: 11783600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
    Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
    Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.
    Manno C; Gesualdo L; D'Altri C; Rossini M; Grandaliano G; Schena FP
    J Nephrol; 2001; 14(4):248-52. PubMed ID: 11506246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproteinuric effect of olmesartan in patients with IgA nephropathy.
    Tomino Y; Kawamura T; Kimura K; Endoh M; Hosoya T; Horikoshi S; Utsunomiya Y; Yasuda T; Toyoda M; Tsuge T; Kaneko K
    J Nephrol; 2009; 22(2):224-31. PubMed ID: 19384840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium channels blockers and progression of kidney disease.
    Ziakka S; Kaperonis N; Ferentinou E; Karakasis F; Ntatsis G; Kourvelou C; Papagalanis N
    Ren Fail; 2007; 29(8):1003-12. PubMed ID: 18067048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis.
    Woo KT; Lau YK; Zhao Y; Liu FE; Tan HB; Tan EK; Stephanie FC; Chan CM; Wong KS
    Cell Mol Immunol; 2007 Jun; 4(3):227-32. PubMed ID: 17601378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis.
    Kramer AB; Ricardo SD; Kelly DJ; Waanders F; van Goor H; Navis G
    J Pathol; 2005 Dec; 207(4):483-92. PubMed ID: 16211543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
    Pozzi C; Del Vecchio L; Locatelli F
    G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical effects of trandolapril in chronic glomerulonephritis patients with renal insufficiency].
    Yoshida A; Takeda A; Fukuda M; Toda S; Morozumi K
    Nihon Jinzo Gakkai Shi; 2000 May; 42(4):333-7. PubMed ID: 10897592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.